Loading...
XNAS
NUWE
Market cap1mUSD
Jul 09, Last price  
2.88USD
1D
0.35%
1Q
-92.42%
Jan 2017
-100.00%
IPO
-100.00%
Name

Nuwellis Inc

Chart & Performance

D1W1MN
XNAS:NUWE chart
P/E
—
P/S
0.13
EPS
—
Div Yield, %
—
Shrs. gr., 5y
202.30%
Rev. gr., 5y
2.14%
Revenues
8m
-5.38%
1,253,1212,731,740422,040108,302400,0250059,000295,00059,0001,289,0003,553,0004,998,0005,511,0007,441,0007,921,0008,543,0008,864,0008,740,0008,270,000
Net income
-18m
L+56.93%
00000-16,196,000-14,065,000-21,758,000-25,587,000-26,583,000-15,792,000-13,382,000-17,032,000-18,114,000-15,836,000-19,554,000-14,525,000-20,209,000-11,165,000-17,521,000
CFO
-11m
L+12.71%
00000-13,089,000-13,083,000-17,362,000-22,644,000-22,989,000-16,292,000-11,920,000-14,560,000-16,367,000-16,572,000-17,843,000-15,149,000-17,937,000-9,591,000-10,810,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company provides Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure, as well as Aquadex SmartFlow system for temporary use in adult and pediatric patients. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.
URL
https://www.nuwellis.com/
IPO date
Feb 16, 2012
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT